Harnessing the microbiome to treat skin disease.

Developing novel therapeutics and consumer health products to treat adverse skin conditions and disease


An emerging biotechnology company that leverages its extensive knowledge of proteomics, genetic engineering and the skin microbiome to discover and develop novel products for the treatment of skin conditions and diseases.

Broad product opportunities developing novel antimicrobials and other therapeutics

The Company’s technology platform offers multiple product opportunities in three areas: (1) consumer health products based on microbial strains and their components; (2) pharmaceuticals based on the delivery of biotherapeutic proteins to the skin via proprietary bacteria strains; and (3) discovery and development of novel bioactive compounds — e.g., antimicrobials and other therapeutics based on the metabolic products of commensal skin bacteria. Azitra’s lead programs are focused on eczema (atopic dermatitis) and ichthyosis vulgaris, inflammatory skin conditions, dry or irritated skin, and orphan skin diseases including Netherton syndrome.

Learn more


The skin microbiome plays a crucial role in maintaining human health and skin appearance

Learn more

Product pipeline includes three Live Biotherapeutic Products (LBPs)

Azitra’s product pipeline includes three therapeutic products in development and one product targeted at the consumer health market. The Company anticipates beginning human testing of its personal use product in late 2018 and initiating Phase 1 clinical studies for its first therapeutic product in the first half of 2019.

View Full Pipeline
handle shape


Azitra is leveraging the microbiome to solve the challenges of skin disease and adverse skin conditions through three strategies:

Learn more